A Bayesian method to estimate the optimal threshold of a longitudinal biomarker

Biometrical Journal

Volumn 52, Issue 3, 2010, Pages 333-347

  Subtil, Fabien ^a,b   Rabilloud, Muriel ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

Diagnostic markers; Longitudinal study; Optimal cut point; Prostate specific antigen; Sensitivity and specificity

Indexed keywords

ANTIGENS; BAYESIAN NETWORKS; DISEASES; INFERENCE ENGINES; NUMERICAL METHODS; STATISTICAL TESTS; UROLOGY;

BAYESIAN METHODS; CREDIBLE INTERVAL; CUT-POINT; DIAGNOSTIC MARKERS; LONGITUDINAL STUDY; OPTIMAL CUT-POINT; OPTIMAL THRESHOLD; PARAMETRIC METHOD; PROSTATE SPECIFIC ANTIGEN; SENSITIVITY AND SPECIFICITY;

BIOMARKERS;

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

BAYES THEOREM; BIOLOGICAL MODEL; HUMAN; LONGITUDINAL STUDY; MALE; METABOLISM; PROSTATIC NEOPLASMS; RECURRENT DISEASE;

BAYES THEOREM; BIOLOGICAL MARKERS; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, BIOLOGICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 77954481272     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.200900242     Document Type: Article

References (29)

1. Bickel, D.R. (2002). Robust estimators of the mode and skewness of continuous data. Computational Statistics and Data Analysis 39, 153-163.
2. Brown, E.R. and Ibrahim, J.G. (2003). A Bayesian semiparametric joint hierarchical model for longitudinal and survival data. Biometrics 59, 221-228.
3. Chaloner, K. and Verdinelli, I. (1995). Bayesian experimental design: a review. Statistical Science 10, 273-304.
4. Chen, L.S., Geisser, S. and Geyer, C.J. (1999). Monte Carlo minimization for sequential control. In: Geisser, S. (Ed.), Diagnosis and Prediction. Springer, New York, 109-130.
5. DeNeef, P. and Kent, D.L. (1993). Using treatment-tradeoff preferences to select diagnostic strategies: linking the ROC curve to threshold analysis. Medical Decision Making 13, 126-132.
6. Escobar, M.D. and West, M. (1998). Computing nonparametric hierarchical models. In: Dey, D., Müller, P. and Sinha, D. (Eds.), Practical Nonparametric and Semiparametric Bayesian Statistics. Springer, New York, 1-22.
7. Fluss, R., Faraggi, D. and Reiser, B. (2005). Estimation of the Youden index and its associated cutoff point. Biometrical Journal 47, 458-472.
8. Ganzer, R., Rogenhofer, S., Walter, B., Lunz, J.-C., Schostak, M., Wieland, W.F. and Blana, A. (2008). PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. European Urology 53, 547-553.
9. Gelman, A., Carlin, J.B., Stern, H.S. and Rubin, D.B. (2004). Bayesian Data Analysis. Chapman & Hall/CRC, London.
10. Gelman, A. and Rubin, D. (1992). Inference from iterative simulation using multiple sequences. Statistical Science 7, 457-511.
11. Jund, J., Rabilloud, M., Wallon, M. and Ecochard, R. (2005). Methods to estimate the optimal threshold for normally or log-normally distributed biological tests. Medical Decision Making 25, 406-415.
12. Laird, N.M., and Ware, J.H. (1982). Random-effects models for longitudinal data. Biometrics 38, 963-974.
13. Leeflang, M. M.G., Moons, K.G.M., Reitsma, J.B. and Zwinderman, A.H. (2008). Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clinical Chemistry 54, 729-737.
14. Pepe, M.S. (2003). The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press, New York.
15. Perkins, N.J. and Schisterman, E.F. (2005). The Youden index and the optimal cut-point corrected for measurement error. Biometrical Journal 47, 428-441.
16. R Development Core Team (2008). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna.
17. Ruopp, M.D., Perkins, N.J., Whitcomb, B.W. and Schisterman, E.F. (2008). Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biometrical Journal 50, 419-430.
18. Schiffer, E. (2009). The 2nd Annual Oncology Biomarkers Conference. Biomarkers in Medicine 3, 203-209.
19. Schisterman, E.F., Faraggi, D., Reiser, B. and Hu, J. (2008). Youden index and the optimal threshold for markers with mass at zero. Statistics in Medicine 27, 297-315.
20. Schisterman, E.F. and Perkins, N. (2007). Confidence intervals for the Youden index and corresponding optimal cut-point. Communications in Statistics: Simulation and Computation 36, 549-563.
21. Soletormos, G., Semjonow, A., Sibley, P.E., Lamerz, R., Petersen, P.H., Albrecht, W., Bialk, P., Gion, M., Junker, F., Schmid, H.-P., van Poppel, H., on behalf of the European Group on Tumor Markers (2005). Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clinical Chemistry 51, 1342-1351.
22. Sox, H.C., Blatt, M.A., Higgins, M.C. and Marton, K.I. (1988). Medical Decision Making. Butterworths, Boston.
23. Subtil, F., Pouteil-Noble, C., Toussaint, S., Villar, E. and Rabilloud, M. (2009). A simple modeling-free method provides accurate estimates of sensitivity and specificity of longitudinal disease biomarkers. Methods of Information in Medicine 48, 299-305.
24. Subtil, F. and Rabilloud, M. (2010). Robust non-linear mixed modelling of longitudinal PSA levels after prostate cancer treatment. Statistics in Medicine 29, 573-587.
25. Tanner, M.A. (1996). Tools for Statistical Inference. Springer, New York.
26. Vickers, A.J. and Elkin, E.B. (2006). Decision curve analysis: a novel method for evaluating prediction models. Medical Decision Making 26, 565-574.
27. Wang, M.-D. and Geisser, S. (2003). Optimal dichotomization for repeated screening tests. Statistics and Probability Letters 62, 61-70.
28. Wang, M.-D. and Geisser, S. (2005). Optimal dichotomization of screening test variables. Journal of Statistical Planning and Inference 131, 191-206.
29. Zheng, Y. and Heagerty, P.J. (2007). Prospective accuracy for longitudinal markers. Biometrics 63, 332-341.